There are currently 1862 ongoing clinical trials involving Ulcerative Colitis
Of the 1862 trials,725 trials are in Phase III
Furthermore, 532 trials are in Phase II
The global pharmaceutical industry is steadily developing new drugs for Ulcerative Colitis, a Gastrointestinal condition. The largest number of ongoing clinical trials for Ulcerative Colitis is conducted in Europe. Asia-Pacific and North America are among some of the other prominent regions engaged in Ulcerative Colitis-related drug trials.
Takeda Pharmaceutical Co Ltd: The leading ongoing Ulcerative Colitis related clinical trial sponsor
Takeda Pharmaceutical Co Ltd is the top sponsor for Ulcerative Colitis-related ongoing clinical trials.
Pfizer Inc, AbbVie Inc, Johnson & Johnson and Eli Lilly and Co are among other notable clinical trial sponsors involved in Ulcerative Colitis. A clinical trial sponsor can be a Company, Government, Individual, or Institution.
Marketed Drugs involving Ulcerative Colitis
Adalimumab (Humira), Ustekinumab (Stelara) and Vedolizumab (Entyvio/ Kynteles) are among the key marketed drugs involving Ulcerative Colitis.
Adalimumab (Humira) is a recombinant human IgG1 monoclonal antibody specific for human tumor necrosis factor (TNF). It functions via Tumor Necrosis Factor (Cachectin or TNF Alpha or Tumor Necrosis Factor Ligand Superfamily Member 2 or TNF a or TNF) Inhibitor mechanism of action. Adalimumab is formulated as injection for subcutaneous route of administration. Adalimumab was first approved in 2002 and is marketed globally in the US, UK, China, Japan, Germany, and France by several prominent pharma giants including AbbVie Inc.
Ustekinumab (Stelara) is a human monoclonal antibody used as immunosuppressant. It functions via Interleukin 12 Subunit Beta Inhibitor: Interleukin 23 Subunit Alpha Inhibitor mechanism of action. Ustekinumab is formulated as an injectable solution for injection, powder for solution and solution for injection in pre-filled syringe and is administered by subcutaneous route and intravenous administration and injectable concentrate solution for subcutaneous route of administration. Ustekinumab was first approved in 2008 and is marketed globally in the US, UK, France, Germany, China and Japan by Janssen Biotech Inc and its subsidiaries.
United States of America
China
Switzerland
United States of America
United States of America
United States of America
United States of America
Germany
France
Switzerland
Don’t wait - discover a universe of connected data & insights with your next search. Browse over 28M data points across 22 industries.
Access more premium companies when you subscribe to Explorer
Contact the team or request a demo to find out how our data can drive your business forward